logo
logo

Epidarex Capital Closes New £102 Million UK Venture Fund to Build Successful Life Science Companies

Epidarex Capital Closes New £102 Million UK Venture Fund to Build Successful Life Science Companies

06/22/20, 6:19 AM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/GB.svgedinburgh
Money raised
£102 million
Epidarex Capital ("Epidarex"), a transatlantic life science venture firm, announces that it has closed Epidarex Capital III UK LP (the "Fund") at £102.1 million. The Fund will build new life science companies based on world-class research and innovation from emerging hubs across the UK, including spinouts from highly regarded universities. Typical initial investments will range from £2 million to £5 million.

Company Info

Company
Epidarex Capital
Location
edinburgh, scotland, united kingdom
Additional Info
Epidarex Capital is a transatlantic venture firm that invests in early-stage, high-growth life science companies in under-ventured markets. Epidarex focuses on providing risk capital and expertise to create, support and build young companies, including spinouts, from leading research institutions in both established and emerging life science hubs. The fund's international management team has a track record of successfully partnering with top scientists and entrepreneurs to develop highly innovative products for the global healthcare market.

Related People